- This event has passed.
ISPOR 6th Latin America Conference
September 15 @ 08:00 - September 17 @ 17:00 UTC+0
ISPOR is recognized globally as the leading educational and scientific organization for health economics and outcomes research (HEOR) and its use in health care decisions. If you want to meet people in the health economics and outcomes research (HEOR) field, discuss the latest trends, and learn from the experts, attend ISPOR São Paulo!
The ISPOR Latin America Conference features three thought-provoking plenary sessions and more than 500 presentations in the form of workshops, issue panels, forums, symposia, and podium and poster presentations on innovative research methods, health policy development using outcomes research, patient preferences, real-world data, and clinical-, economic-, and patient-reported outcomes. ISPOR São Paulo will examine health system reform and sustainability, patient engagement in health care decision making processes, drug development, and regulatory issues through the lens of Driving Better Health Outcomes Through Stakeholder Engagement.
In addition, ISPOR offers a series of pre-Conference short (training) courses on trending topics in the HEOR field. ISPOR short courses range from introductory to advanced and are taught by leading experts in the field, with many incorporating group exercises and hands-on training opportunities.
The ISPOR scope and sphere of influence comprises the international HEOR community: global leaders, policy makers, regulators, researchers, academicians, payers, decision makers, patients, and patient groups. This multistakeholder group is invested in using science and research to make better health care decisions. The diversity in work environments and international scope of attendance provide excellent networking opportunities and stimulating discussions and debate.
Learn more at https://www.ispor.org/Event/Index/2017SaoPaulo.
Mapi's Event Role:
Featured Presenters/Presentations -
W8: USE OF EVIDENCE OF THE REAL WORLD (RWE) IN MAKING DECISIONS IN HEALTH: THE CASES OF ARGENTINA, CHILE AND COLOMBIA * Presented in Spanish
|DISCUSSION LEADERS:||Nahila Justo, MPhil MBA, Scientific Director, Mapi Sweden AB and Karolinska Institute, NVS department, Stockholm, Sweden
Manuel A. Espinoza, MD, MSc, PhD, Professor, Department of Public Health and Chief, Sanitary Technologies Assessment Unit - Clinical Research Center, Faculty of Medicine, Pontifical Catholic University of Chile, Santiago, Chile, and Honorary Visiting Researcher , Center for Health Economics, York University, York, UK
Diego Rosselli, MD, MEd, MHP, Adjunct Professor, Health Economics, Pontificia Universidad Javeriana, Bogotá, Colombia
Sebastian Garcia, MD, MSc, Coordinator, Evaluation Department of Sanitary Technologies and Economic Evaluations, IECS, Buenos Aires, Argentina
|PURPOSE:||Share ideas and notions about the uses of RWE in the international health decision-making process, and describe the current situation and areas of opportunity in Latin America, specifically in Argentina, Chile and Colombia.|
|DESCRIPTION:||The use of RWE to study patterns of treatment, cost, and outcomes of various medical interventions has become an important source of valuable evidence for decision-making by different actors in health systems. RWE can support the design of locally relevant clinical practice guidelines, inform decisions on innovative access schemes, assist in identifying subpopulations for those who are markedly better / worse, contribute to the optimization of clinical trial design, and prioritization of investments in research and development, nurturing various modules of the models for the economic evaluation of technologies minimizing the "black box", as well as contributing to the evaluation of innovative treatments that usually carry high costs. The introductory presentation will address these and other uses in a systematic way, followed by three case studies that will review the current situation of each country in those areas. Following the introduction and the 3 presentations of the national cases (of 12 minutes each), a 15-minute question and answer session is planned in which members of the public will be invited to share their knowledge and experiences on the subject.|
Featured Poster Presentations -
Maksymowych WP1, Walsh J2, Thom H3, Kalyvas C4, Rosal GF5, Porter B6, Gandhi K6, Jugl SM7
1University of Alberta, Edmonton, AB, Canada, 2University of Utah, Salt Lake City, UT, USA, 3University of Bristol, Bristol, UK, 4Mapi Group, Houten, The Netherlands, 5Novartis Biociências SA, Sao Paulo, Brazil, 6Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 7Novartis Pharma AG, Basel, Switzerland
Strand V1, McInnes I2, Thom H3, Hunger M4, Lopes N5, Gandhi K6, Jugl SM7
1Stanford University, Stanford, CA, USA, 2University of Glasgow, Glasgow, UK, 3University of Bristol, Bristol, UK, 4Mapi Group, Munich, Germany, 5Novartis Biociências SA, Sao Paulo, Brazil, 6Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 7Novartis Pharma AG, Basel, Switzerland
PMS6 / L3 / SECUKINUMAB SHOWS HIGHER SYMPTOMATIC IMPROVEMENT VERSUS ETANERCEPT IN PSORIATIC ARTHRITIS: COMPARATIVE EFFECTIVENESS UP TO 24 WEEKS ASSESSED BY MATCHING-ADJUSTED INDIRECT COMPARISON
1Swedish Medical Center and University of Washington, Seattle, WA, USA, 2Cardiff University, Cardiff, UK, 3University of Bristol, Bristol, UK, 4Mapi Group, Houten, The Netherlands, 5Novartis Biociências SA, Sao Paulo, Brazil, 6Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 7Novartis Pharma AG, Basel, Switzerland, 8University of Queensland, Brisbane, Australia